Pathophysiological Mechanisms in Migraine and the Identification of New Therapeutic Targets Kristian Agmund HaanesLars Edvinsson Leading Article 15 April 2019 Pages: 525 - 537
The Possible Role of the Angiotensin System in the Pathophysiology of Schizophrenia: Implications for Pharmacotherapy SeungJu Jackie OhXiaoduo Fan Leading Article 16 April 2019 Pages: 539 - 547
Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis Koen DemyttenaereJohan DetrauxKristof Vansteelandt Systematic Review 07 May 2019 Pages: 549 - 566
Buprenorphine Treatment for Opioid Use Disorder: An Overview Matisyahu ShulmanJonathan M. WaiEdward V. Nunes Review Article 06 May 2019 Pages: 567 - 580
Association of Hyponatraemia and Antidepressant Drugs: A Pharmacovigilance–Pharmacodynamic Assessment Through an Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) Database Faizan MazharMarco PozziCarla Carnovale Original Research Article 11 April 2019 Pages: 581 - 592
Pharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients with Treatment-Resistant Epilepsy James W. WhelessDennis Dlugosthe INS011-14-029 Study Investigators Original Research Article Open access 02 May 2019 Pages: 593 - 604
Safety, Pharmacokinetics and Pharmacodynamics of TNHH, a Novel Targeted Neutrophil-Inhibitory Hirulog Hybrid Glycoprotein, in Healthy Volunteers Zhong Ping GouZi Hui SongLi Zheng Original Research Article 15 May 2019 Pages: 605 - 614
Comment on: “Phytomedicines in the Treatment of Migraine” Hans-Christoph Diener Letter to the Editor 30 April 2019 Pages: 615 - 615
Authors’ Reply to Diener: “Phytomedicines in the Treatment of Migraine” Thilinie RajapakseWilliam Jeptha Davenport Letter to the Editor 30 April 2019 Pages: 617 - 618
